Background: Financial constraints challenge evidence of the effectiveness of dermatological inpatient management. Objective: To evaluate the effectiveness of hospitalization in atopic dermatitis and psoriasis regarding initial and sustained benefits. Methods: Prospective study on adults with psoriasis vulgaris (n = 22) and atopic dermatitis (n = 14). At admission, discharge, and 3 months after discharge, validated outcomes of objective and subjective disease severity were assessed by trained investigators. Results: Hospitalization resulted in substantial benefit in quality of life and clinical disease severity. Looking at mean scores, the observed benefit appeared stable until 3-month follow-up. The analysis of individual patient data revealed significant changes in disease severity between discharge and 3-month follow-up with some patients relapsing, others further improving. Reasons for hospitalization and treatment performed were not related to sustained benefit. Conclusions: In psoriasis vulgaris and atopic dermatitis, hospitalization effectively improved quality of life and clinical disease severity. Further research should focus on prognostic factors for sustained improvement.

1.
Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236–244.
2.
Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA: The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9:131–135.
3.
Langley RG, Krueger GG, Griffiths CE: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 (suppl 2):ii18–ii23.
4.
Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121–128.
5.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–407.
6.
Ellis CN, Prendergast MM, Tokar M, Tong K: Quantifying costs associated with atopic dermatitis. J Manag Care Pharm 2003;9:278–279.
7.
Finlay AY: Quality of life in atopic dermatitis. J Am Acad Dermatol 2001;45:S64–S66.
8.
Williams HC: Epidemiology of atopic dermatitis: recent advances and future predictions. Curr Probl Dermatol 1999;28:9–17.
9.
Williams HC: Clinical practice. Atopic dermatitis. N Engl J Med 2005;352:2314–2324.
10.
Seiffert K, Hilbert E, Schaechinger H, Zouboulis CC, Deter HC: Psychophysiological reactivity under mental stress in atopic dermatitis. Dermatology 2005;210:286–293.
11.
Ayyalaraju RS, Finlay AY, Dykes PJ, Trent JT, Kirsner RS, Kerdel FA: Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: a comparative study. J Am Acad Dermatol 2003;49:249–254.
12.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) – A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.
13.
Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281–285.
14.
Lewis VJ, Finlay AY: Two decades experience of the Psoriasis Disability Index. Dermatology 2005;210:261–268.
15.
Uttjek M, Dufaker M, Nygren L, Stenberg B: Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol 2004;84:37–43.
16.
Finlay AY: Psoriasis from the patient’s point of view. Arch Dermatol 2001;137:352–353.
17.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–284.
18.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136–139.
19.
Kurwa HA, Finlay AY: Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995;133:575–578.
20.
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–926.
21.
Lewis V, Finlay AY: 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004;9:169–180.
22.
Khilij FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002;147(suppl 62):50.
23.
Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D: Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318–322.
24.
Fredriksson T, Pettersson U: Severe psoriasis – Oral therapy with a new retinoid. Dermatologica 1978;157:238–244.
25.
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11–18.
26.
Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bavinck JN, Williams H: Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. J Invest Dermatol 2003;120:738–741.
27.
Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, Eichenfield LF, Cherill R, Hanifin J: Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1,550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004;150:96–102.
28.
Schmitt J, Wozel G: The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194–199.
29.
Dupont WD, Plummer WD: PS power and sample size program available for free on the Internet. Control Clin Trials 1997;18:274.
30.
Stata Corporation: Stata 8 Reference Manual. College Station, Stata Corporation, 2003.
31.
Stata Corporation: Stata Statistical Software: Release 8.0. College Station, Stata Corporation, 2002.
32.
Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, Taylor JR, Schwartzberg JB: Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000;43:858–860.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.